SEC Comment Letter for Sarepta Therapeutics, Inc. (SRPT) (CIK 0000873303) (SRPT) — Apr 13, 2020
Sarepta Therapeutics, Inc. (SRPT) (CIK 0000873303)
Date: April 13, 2020 · CIK: 0000873303 · Accession: 0000000000-20-003160
AI Filing Summary & Sentiment
File numbers found in text: 001-14895
Letter
April 13, 2020 Douglas S. Ingram President and Chief Executive Officer Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Re:Sarepta Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 8, 2020 File No. 001-14895 Dear Mr. Ingram: We have reviewed your filing and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to our comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to our comment, we may have additional comments. Preliminary Proxy Statement on Schedule 14A Restated Certificate Amendment (Proposal 3), page 19 1.Please revise the proxy statement to indicate whether you currently have any plans, arrangements or understandings, written or oral, to issue any of the authorized but unissued shares that would become available as a result of the amendment to the Restated Certificate.
FirstName LastNameDouglas S. Ingram Comapany NameSarepta Therapeutics, Inc. April 13, 2020 Page 2 FirstName LastName Douglas S. Ingram Sarepta Therapeutics, Inc. April 13, 2020 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 or Irene Paik at (202) 551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Raymond J. Grant, Esq.
Show Raw Text
April 13, 2020
Douglas S. Ingram
President and Chief Executive Officer
Sarepta Therapeutics, Inc.
215 First Street, Suite 415
Cambridge, MA 02142
Re:Sarepta Therapeutics, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed April 8, 2020
File No. 001-14895
Dear Mr. Ingram:
We have reviewed your filing and have the following comment. In our comment, we
may ask you to provide us with information so we may better understand your disclosure.
Please respond to our comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to our comment, we may have additional comments.
Preliminary Proxy Statement on Schedule 14A
Restated Certificate Amendment (Proposal 3), page 19
1.Please revise the proxy statement to indicate whether you currently have any
plans, arrangements or understandings, written or oral, to issue any of the authorized
but unissued shares that would become available as a result of the amendment to the
Restated Certificate.
FirstName LastNameDouglas S. Ingram
Comapany NameSarepta Therapeutics, Inc.
April 13, 2020 Page 2
FirstName LastName
Douglas S. Ingram
Sarepta Therapeutics, Inc.
April 13, 2020
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 or Irene Paik at (202) 551-6553 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Raymond J. Grant, Esq.